A Phase 1 Dose Escalation Study of DS-3032b, an Oral Murine Double Minute (mdm2) Oncogene Inhibitor, in Subjects With Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or High-Risk Myelodysplastic Syndrome (MDS)

Trial Profile

A Phase 1 Dose Escalation Study of DS-3032b, an Oral Murine Double Minute (mdm2) Oncogene Inhibitor, in Subjects With Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or High-Risk Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs DS 3032b (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 30 Mar 2017 Planned number of patients changed from 38 to 100.
    • 30 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019.
    • 30 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top